Sars Cov -2.jpg
Sars Cov-2 thumbnail.jpg

COVID Response

Facing the challenge of SARS Cov-2

Offering BBI’s expertise in the fight against Covid-19 

BBI’s expertise in immunoassay and lateral flow is at your disposal. 

As a leading provider of immunoassay reagents, gold labels, and rapid lateral flow assay manufacturing services, we can: 

  • Accelerate tests to market 
  • Increase the availability of rapid immunoassays for healthcare professionals and public 
  • Mobilise supply chain capacity 
  • Aid the collection, interpretation and communication of results in this dynamic crisis 

BBI Solutions will remove any significant barrier for the goal of increasing accessibility of your tests for embattled healthcare providers worldwide and for supporting the diagnostic testing infrastructure in all countries affected. 

In any crisis, tried and trusted approaches and partners are even more in demand to separate the claims from the facts, especially when people’s lives depend on the results. BBI’s reputation in our industry is exemplary for the level of quality, service and responsiveness we provide, and we are ready to do our part in these times. 

If you are an IVD manufacturer then speak to us about your urgent diagnostics component needs or manufacturing bottlenecks. Contact us 


Message from our CEO - BBI Solution’s response to Novel Coronavirus (COVID-19) 

As COVID-19 (the coronavirus) continues to impact the global community, I want to personally update you on the steps we have taken to ensure business continuity for all our customers around the world. 

Based on guidance from the World Health Organization, we have augmented our already robust Business Continuity Plan with specific steps to account for COVID-19. 

To date, these actions include: 

  • Daily monitoring of suppliers, stocks and supply chain to minimise disruption and ensure the best possible flow of goods both into and out of our business. 
  • Implementation of policies to minimise our team’s risk of exposure to the virus and maximise our ability to serve you with both reagents and services. 
  • Working proactively with our customers to de-risk their supply chain and maximise the ability of our manufacturing facilities to respond to their needs. 

We are acutely aware of our role in the provision of healthcare services globally and aim to remain as adaptable as possible in a rapidly changing environment. By working in close partnership with you, our customers, we hope to play a small part in helping us all mitigate the consequences of this global crisis. As a valued BBI customer, our customer service and sales teams are at your disposal to ensure we are best placed to meet your ongoing requirements. 

Below you will find answers to some Frequently Asked Questions containing more information on how BBI Solutions are responding to the evolving COVID-19 situation. If your question is not answered below, please submit any further questions you may have here. This webpage will be updated regularly. 

In the meantime, please continue to send your purchase orders and request for quotations to, and our team will acknowledge your requests as per our standard processes. 

It goes without saying that, in the current environment, the health and safety of our employees, customers and partners are paramount. These are unprecedented times for everyone, and the situation is changing daily. We are committed to maintaining our business operations and ensuring you continue to receive the highest quality service without disruption.  

We thank you for your loyal custom, and we greatly value our collaboration at this challenging time for all. 

Mario Gualano 

Group CEO 



Frequently Asked Questions - COVID-19 

Q. What business continuity/contingency strategies are you pursuing in case this is a prolonged and worsening situation? 

A. Our Crisis Management Team has been deployed and is meeting daily. We are continuously monitoring Government and International Guidelines to ensure we are implementing best practice for our contingencies - this is changing on a regular basis. 

Q. Can you please list the products affected and lead time implications due to the impact? Please also provide a copy of your supply chain mitigation plan or route investigation that is in place regarding resolution of any possible issues. 

A. We are currently adhering to all confirmed product delivery lead times. However, the situation is in constant flux and we are proactively engaging with our customers to forward plan your requirements as soon as possible. Please visit our website for up to date information. 

Q. Can you please confirm what measures are in place to secure the safety of your products? 

A. The Centres for Disease Control (CDC) have stated that, based on current data available, there is very low risk of spread from products or packaging, such as cardboard, that are shipped over a period of days or weeks at ambient temperatures. 

There is currently no evidence or reported instances to support transmission of COVID-19 associated with imported goods. We are monitoring suppliers, stocks and supply chain daily in order to minimise disruption and ensure the best possible flow of goods both into and out of our business. 

Q. What measures are in place to protect visitors to sites? 

A. All our offices and production sites at the current time are open, firmly adhering to WHO recommendations and guidelines. The safety and security of our staff and visitors remains of the highest priority to us and we will continue to ensure and update our processes to secure the highest standards of cleanliness and hygiene. 

Q) How is BBI offering their services in the fight against COVID-19? 

A) We are proud to have been chosen to be part of a consortium of the UK’s top diagnostic companies to rapidly develop and roll out millions of coronavirus tests. As part of the Government’s National Testing Plan, the expertise and resources of the UK’s world-leading life sciences industries are being pooled to build a large British diagnostics industry as quickly as possible. The “UK-Rapid Test Consortium, UK-RTC” comprises Oxford University, BBI Solutions, Abingdon Health, CIGA Healthcare and Omega Diagnostics. The consortium has been launched to design and develop a new antibody test to determine whether people have developed immunity after contracting the virus. 

As a worldwide market-leading provider of diagnostic reagents and rapid test/lateral flow contract services, BBI Solutions are dedicated to using our 35 years of expertise to help the fight against COVID-19. At this exceptional time, BBI Solutions offer several related products and services that support our core mission of 'serving the science of diagnostics'.  



Receive regular industry insights and the latest BBI Solutions' news & product launch information by signing up to our Newsletter